Ignite Creation Date:
2024-05-06 @ 4:32 PM
Last Modification Date:
2024-10-26 @ 2:11 PM
Study NCT ID:
NCT05014724
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2024-01-25
First Post:
2021-08-19
Brief Title:
CIDP07 Rozanolixizumab Post Trial Access Program the PTA
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Study Overview
Official Title:
CIDP07 Rozanolixizumab Post Trial Access Program the PTA
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Post Trial Access PTA Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial NCT04051944 and are continuing to derive benefit from treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None